KOD 📈 Kodiak Sciences - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US50015M1099
KOD: Eye, Disease, Treatment, Retinal, Medication
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Web URL: https://kodiak.com
Additional Sources for KOD Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
KOD Stock Overview
| Market Cap in USD | 525m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2018-10-04 |
KOD Stock Ratings
| Growth 5y | -78.4% |
| Fundamental | -60.9% |
| Dividend | - |
| Rel. Strength Industry | 46343 |
| Analysts | 3.13/5 |
| Fair Price Momentum | 8.46 USD |
| Fair Price DCF | - |
KOD Dividends
No Dividends PaidKOD Growth Ratios
| Growth Correlation 3m | 98.5% |
| Growth Correlation 12m | -3.9% |
| Growth Correlation 5y | -81.3% |
| CAGR 5y | -31.81% |
| CAGR/Mean DD 5y | -0.47 |
| Sharpe Ratio 12m | 1.68 |
| Alpha | 189.99 |
| Beta | 1.58 |
| Volatility | 115.64% |
| Current Volume | 822k |
| Average Volume 20d | 535.5k |
What is the price of KOD stocks?
As of January 01, 2025, the stock is trading at USD 9.95 with a total of 822,007 shares traded.
Over the past week, the price has changed by +0.81%, over one month by +33.92%, over three months by +281.23% and over the past year by +212.89%.
As of January 01, 2025, the stock is trading at USD 9.95 with a total of 822,007 shares traded.
Over the past week, the price has changed by +0.81%, over one month by +33.92%, over three months by +281.23% and over the past year by +212.89%.
Is Kodiak Sciences a good stock to buy?
No, based on ValueRay Fundamental Analyses, Kodiak Sciences (NASDAQ:KOD) is currently (January 2025) a stock to sell. It has a ValueRay Fundamental Rating of -60.88 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KOD as of January 2025 is 8.46. This means that KOD is currently overvalued and has a potential downside of -14.97%.
No, based on ValueRay Fundamental Analyses, Kodiak Sciences (NASDAQ:KOD) is currently (January 2025) a stock to sell. It has a ValueRay Fundamental Rating of -60.88 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KOD as of January 2025 is 8.46. This means that KOD is currently overvalued and has a potential downside of -14.97%.
Is KOD a buy, sell or hold?
Kodiak Sciences has received a consensus analysts rating of 3.13. Therefor, it is recommend to hold KOD.
Kodiak Sciences has received a consensus analysts rating of 3.13. Therefor, it is recommend to hold KOD.
- Strong Buy: 2
- Buy: 0
- Hold: 3
- Sell: 3
- Strong Sell: 0
What are the forecast for KOD stock price target?
According to ValueRays Forecast Model, KOD Kodiak Sciences will be worth about 9.5 in January 2026. The stock is currently trading at 9.95. This means that the stock has a potential downside of -4.72%.
According to ValueRays Forecast Model, KOD Kodiak Sciences will be worth about 9.5 in January 2026. The stock is currently trading at 9.95. This means that the stock has a potential downside of -4.72%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 6.7 | -33% |
| Analysts Target Price | 4 | -59.8% |
| ValueRay Target Price | 9.5 | -4.7% |